FDA recommends using imaging of the sinuses as a secondary efficacy endpoint for drugs being developed to treat chronic rhinosinusitis with nasal polyps (CRSwNP).
Semi-automated quantitative measurements of sinus inflammation from 3D CT imaging correlate well with clinical outcomes.
